Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.80 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5302319 | 1.00 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL29633045 | 1.00 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL2556577 | 1.00 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5302329 | 1.00 | HTR2A (0.80) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL2761491 | 0.98 | HTR2A (0.77) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL2761490 | 0.98 | HTR2A (0.77) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5304945 | 0.98 | HTR2A (0.77) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5304943 | 0.98 | HTR2A (0.77) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5303673 | 0.97 | HTR2A (0.74) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5305069 | 0.97 | HTR2A (0.74) | HTR2ATAAR1HTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2025-09-11 | — | — | US | claimed |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | LDN Pharma Limited (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| US-20240285613-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| EP-4358961-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B OR 2C AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-4358943-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| WO-2022269266-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B OR 2C AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| WO-2022269264-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| EP-3687576-A1 | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | GW Research Limited (GB) | 2020-08-05 | — | — | EP | claimed |
| US-20200237683-A1 | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2020-07-30 | — | — | US | claimed |
| CN-111201039-A | Use of cannabidiol in combination with a 5-HT2B receptor agonist or amphetamine for the treatment of epilepsy | 吉伟研究有限公司 | 2020-05-26 | — | — | CN | claimed |
| WO-2019064031-A1 | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | GW Research Limited (GB) | 2019-04-04 | — | — | WO | claimed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010151258-A1 | METHODS OF TREATING PSYCHOLOGICAL CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237683-A1 | USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINS IN THE TREATMENT OF EPILEPSY | HTR2B, CNR2, HTR5A | HTR2A 14/4885TAAR1 461/4885HTR1A 11/4885 |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | HTR2C, HTR2B, HTR2A | HTR2A 3/4885TAAR1 47/4885HTR1A 5/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885TAAR1 1075/4885HTR1A 29/4885 |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | VDR, OPRD1, HTR1A | HTR2A 11/4885TAAR1 45/4885HTR1A 3/4885 |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | HTR3A, HTR3C, HTR1A | HTR2A 10/4885TAAR1 31/4885HTR1A 3/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR2A 19/4885TAAR1 51/4885HTR1A 22/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | HTR2A 2491/4885TAAR1 543/4885HTR1A 1360/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 9/4885TAAR1 121/4885HTR1A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.